Generic Drug Puzzle: Why Did ANDA Submissions Spike Again?
Executive Summary
Jump in March may have been "happenstance," but also could be concerning as US ANDA submissions reach near record pace.
You may also be interested in...
FDA's Post-Shutdown ANDA Bolus Could Be Massive
More than 300 generic drug applications might be officially filed when the shutdown ends, substantially increasing stress on assessors and other Office of Generic Drugs staff.
FDA Contradicts AAM's Generic Market Consolidation Argument
As the generic industry trade group warns shortages could emerge as number of manufacturers contracts, US FDA says many new firms gaining approvals and identifying facilities.
FDA Contradicts AAM's Generic Market Consolidation Argument
As the generic industry trade group warns shortages could emerge as number of manufacturers contracts, US FDA says many new firms gaining approvals and identifying facilities.